Published in J Transl Med on February 18, 2013
Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res (2014) 8.11
Nodal metastasis in cervical cancer occurs in clearly delineated fields of immune suppression in the pelvic lymph catchment area. Oncotarget (2015) 0.87
Immunoscore and Immunoprofiling in cancer: an update from the melanoma and immunotherapy bridge 2015. J Transl Med (2016) 0.82
The role of immunotherapy in solid tumors: report from the Campania Society of Oncology Immunotherapy (SCITO) meeting, Naples 2014. J Transl Med (2014) 0.79
CpG-1826 immunotherapy potentiates chemotherapeutic and anti-tumor immune responses to metronomic cyclophosphamide in a preclinical glioma model. Cancer Lett (2015) 0.77
Implications of Lymphatic Transport to Lymph Nodes in Immunity and Immunotherapy. Annu Rev Biomed Eng (2016) 0.77
microRNA Expression in Sentinel Nodes from Progressing Melanoma Patients Identifies Networks Associated with Dysfunctional Immune Response. Genes (Basel) (2016) 0.75
Lymph Nodes and Cancer Metastasis: New Perspectives on the Role of Intranodal Lymphatic Sinuses. Int J Mol Sci (2016) 0.75
High PD-1 expression on regulatory and effector T-cells in lung cancer draining lymph nodes. ERJ Open Res (2017) 0.75
Immune biomarkers for prognosis and prediction of responses to immune checkpoint blockade in cutaneous melanoma. Oncoimmunology (2017) 0.75
Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol (2009) 23.08
Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest (2004) 4.27
Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature (2001) 3.99
Profile of immune cells in axillary lymph nodes predicts disease-free survival in breast cancer. PLoS Med (2005) 2.12
Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma. Cancer Res (2003) 1.60
Sentinel lymph nodes show profound downregulation of antigen-presenting cells of the paracortex: implications for tumor biology and treatment. Mod Pathol (2001) 1.48
Prediction of metastatic melanoma in nonsentinel nodes and clinical outcome based on the primary melanoma and the sentinel node. Mod Pathol (2004) 1.32
Density of DC-LAMP(+) mature dendritic cells in combination with activated T lymphocytes infiltrating primary cutaneous melanoma is a strong independent prognostic factor. Cancer Immunol Immunother (2007) 1.28
Redundancy of direct priming and cross-priming in tumor-specific CD8+ T cell responses. J Immunol (2001) 1.27
The dynamics of the T-cell antitumor response: chemokine-secreting dendritic cells can prime tumor-reactive T cells extranodally. Cancer Res (2001) 1.19
Simultaneous Foxp3 and IDO expression is associated with sentinel lymph node metastases in breast cancer. BMC Cancer (2009) 1.14
T-cell activation marker expression on tumor-infiltrating lymphocytes as prognostic factor in cutaneous malignant melanoma. Clin Cancer Res (2004) 1.04
Analysis of dendritic cells in tumor-free and tumor-containing sentinel lymph nodes from patients with breast cancer. Breast Cancer Res (2004) 1.04
Presence of the T-cell activation marker OX-40 on tumor infiltrating lymphocytes and draining lymph node cells from patients with melanoma and head and neck cancers. Am J Surg (1997) 1.03
In situ T cells in melanoma. Cancer Immunol Immunother (1999) 1.01
Long-term protective effect of mature DC-LAMP+ dendritic cell accumulation in sentinel lymph nodes containing micrometastatic melanoma. Clin Cancer Res (2007) 0.99
High FOXP3+ regulatory T-cell density in the sentinel lymph node is associated with downstream non-sentinel lymph-node metastasis in gastric cancer. Br J Cancer (2011) 0.98
Regional immunity in melanoma: immunosuppressive changes precede nodal metastasis. Mod Pathol (2010) 0.97
Indoleamine 2,3-dioxygenase, a new prognostic marker in sentinel lymph nodes of melanoma patients. Eur J Cancer (2011) 0.93
Accumulation of regulatory T cells in sentinel lymph nodes is a prognostic predictor in patients with node-negative breast cancer. Eur J Cancer (2009) 0.93
Selective Modulation of Paracortical Dendritic Cells and T-Lymphocytes in Breast Cancer Sentinel Lymph Nodes. Breast J (2000) 0.92
Infiltration of antitumor immunocytes into the sentinel node in gastric cancer. J Gastrointest Surg (2003) 0.89
Metastasis to sentinel lymph nodes in breast cancer is associated with maturation arrest of dendritic cells and poor co-localization of dendritic cells and CD8+ T cells. Virchows Arch (2011) 0.89
FOXP3+ cell density in primary tumor has no prognostic impact in patients with cutaneous malignant melanoma. Pathol Oncol Res (2010) 0.89
Cytokine expression and dendritic cell density in melanoma sentinel nodes. Melanoma Res (2005) 0.88
Plasmacytoid dendritic cells represent a major dendritic cell subset in sentinel lymph nodes of melanoma patients and accumulate in metastatic nodes. Clin Immunol (2007) 0.88
Immune response in melanoma: an in-depth analysis of the primary tumor and corresponding sentinel lymph node. Mod Pathol (2012) 0.87
Immunohistochemical analysis of primary breast tumors and tumor-draining lymph nodes by means of the T-cell costimulatory molecule OX-40. Am J Surg (2000) 0.83
Presence of mature DC-Lamp+ dendritic cells in sentinel and non-sentinel lymph nodes of breast cancer patients. Eur J Surg Oncol (2007) 0.80
Identification of identical TCRs in primary melanoma lesions and tumor free corresponding sentinel lymph nodes. Cancer Immunol Immunother (2005) 0.79
Infiltration of dendritic cells and NK cells into the sentinel lymph node in oral cavity cancer. Oral Oncol (2005) 0.78
Relationship between sentinel lymph node status and regression of primary malignant melanoma. Melanoma Res (2005) 0.78
Clinical significance of sentinel lymph node involvement in malignant melanoma. Pathol Oncol Res (2003) 0.77
Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med (2014) 5.43
Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study. Lancet Oncol (2013) 2.13
Partial breast irradiation with interstitial 60CO brachytherapy results in frequent grade 3 or 4 toxicity. Evidence based on a 12-year follow-up of 70 patients. Int J Radiat Oncol Biol Phys (2004) 2.09
Density of DC-LAMP(+) mature dendritic cells in combination with activated T lymphocytes infiltrating primary cutaneous melanoma is a strong independent prognostic factor. Cancer Immunol Immunother (2007) 1.28
Prognostic impact of B-cell density in cutaneous melanoma. Cancer Immunol Immunother (2011) 1.05
T-cell activation marker expression on tumor-infiltrating lymphocytes as prognostic factor in cutaneous malignant melanoma. Clin Cancer Res (2004) 1.04
[Survival chances of Hungarian cancer patients in the National Cancer Registry]. Magy Onkol (2008) 0.95
FOXP3+ cell density in primary tumor has no prognostic impact in patients with cutaneous malignant melanoma. Pathol Oncol Res (2010) 0.89
Efficacy of different hemostatic devices for severe liver bleeding: a randomized controlled animal study. Surg Innov (2010) 0.87
Neoadjuvant immunotherapy of oral squamous cell carcinoma modulates intratumoral CD4/CD8 ratio and tumor microenvironment: a multicenter phase II clinical trial. J Clin Oncol (2005) 0.83
In vitro and in vivo antitumor effect of 2-methoxyestradiol on human melanoma. Int J Cancer (2004) 0.83
Glucocorticoid receptor expression and antiproliferative effect of dexamethasone on human melanoma cells. Pathol Oncol Res (2011) 0.82
Association of microvessel density with infiltrating cells in human cutaneous malignant melanoma. Pathol Oncol Res (2007) 0.81
Low-dose irradiation and short-exposure suboptimal-dose paclitaxel adversely modulate metastatic potential of squamous carcinoma cells. Strahlenther Onkol (2003) 0.81
Loss of vascular adhesion protein-1 expression in intratumoral microvessels of human skin melanoma. Melanoma Res (2004) 0.80
Spectral and complexity features of the EEG changed by visual input in a case of subcortical stroke compared to healthy controls. Clin Neurophysiol (2006) 0.80
[Metachronous metastasis from rectal adenocarcinoma to the penis--case report]. Magy Onkol (2009) 0.78
Relationship between sentinel lymph node status and regression of primary malignant melanoma. Melanoma Res (2005) 0.78
Revisiting CB1 receptor as drug target in human melanoma. Pathol Oncol Res (2012) 0.77
PET identifies transitional metabolic change in the spinal cord following a subthreshold dose of irradiation. Pathol Oncol Res (2004) 0.77
Sex-dependent liver colonization of human melanoma in SCID mice--role of host defense mechanisms. Clin Exp Metastasis (2012) 0.77
[Tissue integration of various silicone-coated polypropylene surgical mesh]. Magy Seb (2010) 0.77
Ectopic lymphoid structures in primary cutaneous melanoma. Pathol Oncol Res (2014) 0.77
The novel panel assay to define tumor-associated antigen-binding antibodies in patients with metastatic melanomas may have diagnostic value. Immunol Res (2015) 0.76
Molecular pathology of tumor metastasis III. Target array and combinatorial therapies. Pathol Oncol Res (2003) 0.76
[Standard CHOP immuno-chemotherapy for primary mediastinal lymphomas]. Orv Hetil (2011) 0.76
Psychological changes in melanoma patients during ipilimumab treatment compared to low-dose interferon alpha therapy-a follow-up study of first experiences. Pathol Oncol Res (2014) 0.76
Intracerebral Human Lymphoma - An Experimental Model. Pathol Oncol Res (1996) 0.76
Melanoma screening in a hungarian nuclear power plant. Pathol Oncol Res (2012) 0.75
Pericardial tamponade caused by tumor hemorrhage--a rare complication of metastatic testicular choriocarcinoma. Pathol Oncol Res (2014) 0.75
[Main treatment and preventive measures for hand-foot syndrome, a dermatologic side effect of cancer therapy]. Magy Onkol (2011) 0.75
Comparative immunohistochemical study of tissue integration of macroporous and laminar surgical meshes. Histol Histopathol (2011) 0.75
[Certifying Examination for Special Qualification in Dermatopathology]. Orv Hetil (2006) 0.75
[Epidemiology of malignant melanoma (Clinical experience at the National Institute of Oncology in Hungary)]. Orv Hetil (2011) 0.75
[Spectral EEG-characteristics of subcortical ischemic brain lesion--a case study]. Ideggyogy Sz (2006) 0.75
[New TNM classification (AJCC 2009) and the pathological significance of sentinel lymph node biopsy in malignant melanoma]. Magy Onkol (2013) 0.75
[Prognostic significance of sex steroid and hypophyseal hormones in head and neck squamous cell carcinoma]. Magy Onkol (2003) 0.75
Increase of hypophyseal hormone levels in male head and neck cancer patients. Pathol Oncol Res (2007) 0.75
[Long-term experience with multidisciplinary therapy of twenty-six patients with dermatofibrosarcoma protuberans]. Orv Hetil (2009) 0.75
Tumor-infiltrating immune cells as potential biomarkers predicting response to treatment and survival in patients with metastatic melanoma receiving ipilimumab therapy. Cancer Immunol Immunother (2017) 0.75
[An interdisciplinary malignancy, the lung cancer in Hungary in 2006: epidemiology, prevention and access to therapy]. Magy Onkol (2006) 0.75
[Serum levels of sex steroid and pituitary hormones in chronic alcoholics and head and neck cancer patients as compared to normal controls]. Magy Onkol (2003) 0.75
[Changes in EEG-complexity after subcortical ischemic brain damage]. Ideggyogy Sz (2006) 0.75
[The importance of fine needle aspiration cytology in the management of recurrent and metastatic melanoma]. Orv Hetil (2012) 0.75
[Results of immuno-chemotherapeutic treatment of patients with diffuse large B-cell lymphoma]. Orv Hetil (2009) 0.75
[Role of simultaneous pancreas-kidney transplantation in the treatment of diabetes mellitus]. Orv Hetil (2013) 0.75
[Detection of late ototoxic side effect of cisplatin by distortion otoacoustic emission (DPOAE)]. Magy Onkol (2007) 0.75
Parallel expression of alphaIIbbeta3 and alphavbeta3 integrins in human melanoma cells upregulates bFGF expression and promotes their angiogenic phenotype. Int J Cancer (2005) 0.75
Ligand-mimetic anti-alphaIIb beta3 antibody PAC-1 inhibits tyrosine signaling, proliferation and lung colonization of melanoma cells. Pathol Oncol Res (2005) 0.75
[A new method for prosthetisation of vascular patients with lower limb amputation: initial experiences with osseointegration technique]. Magy Seb (2009) 0.75
[Recurrent acral lentigous melanoma successfully treated with Mohs' micrographic surgery. Case report and review of the literature]. Orv Hetil (2009) 0.75
[Etiologic factors of malignant melanoma in young adults]. Orv Hetil (2005) 0.75